2nd Strok@lliance meeting was a success!

This year again, Strok@lliance aimed at bridging the gap between laboratory and clinical practices. Therefore, the second annual meeting of Strok@lliance took place at La Maison de la Chimie in Paris on June 5, 2018.

During the conference, key opinion leaders in the field of stroke enlightened the reality of post-stroke deficit evaluation and rehabilitation in both the setting of clinical trials and medical cares. The event gathered nearly 40 participants, coming from both the public and the industry. It was also the opportunity for Strok@lliance’s team to share some innovative behavioral tests and research strategies in rodents, supporting the major impact of preclinical research on the design of clinical studies.

Follow the video release of the conferences during next weeks on strok@lliance website (sucscribe via our contact form).

Thanks again to all the attendees, see you next year for the Strok@lliance 3rd annual meeting.


The Strok@lliance’s Team

2nd STROK@LLIANCE annual meeting


June 5th, 2018 – 10:00 AM – 4:30 PM
28 Rue Saint-Dominique, 75007 Paris


Post-stroke deficits and recovery from bench to patient’s bed
Any translational end-points to come?



For decades, preclinical stroke studies have failed to predict neuroprotective drug efficacy in clinic. Many reasons have been pointed out, among them the difficulty to induce reproducible and long-lasting functional outcomes in preclinical studies. It is a critical issue considering that clinical interventions focus on patient functional deficits and recovery.

It is time to start rethinking post-stroke behavioral testing in preclinical studies. This point will be the subject of presentations and discussions during our annual meeting on June 5th in Paris. This year again, Strok@lliance’s meeting will aims at bridging the gap between laboratory and clinical practices.
For one day, neurologists, clinicians and researchers will enlighten the reality of post-stroke deficit evaluation and rehabilitation in both the setting of clinical trials and medical cares. Some innovative behavioral tests and research strategies in rodents will be presented before a debate where clinician will share their vision of the value and needs in current preclinical behavioral studies.

Come to share your points of view and listen to the conferences on June 5th 2018!


Free Registration!



Download the full program



Strok@lliance is growing to provide its customers with high level and original services in preclinical stroke studies.

You have now the opportunity to join a young and dynamic team looking for challenge in a high level scientific and technologic environment !


Strok@lliance invites applications from eligible candidates for recruitment of a Scientific Laboratory Technician in stroke preclinical testing.

The company is looking for individuals who wants to contribute their skills to provide excellent work in a challenging and rewarding environment.


Find the application details here.



STROK@LLIANCE, Newsletter #4


Focus on an innovative model of thromboembolic stroke reproducing the clinical situation


Recombinant tissue-type plasminogen activator (rt-PA) is the only approved drug treatment at the acute phase of ischemic stroke in the US and Europe. However, rt-PA has a short therapeutic window (4.5h after stroke onset), mainly because of the increased risk of hemorrhagic transformation from this time. Thus, only a few percentage of stroke patients will benefit from rt-PA-induced thrombolysis.

These last two decades, despite the efforts made to improve fibrinolysis or to develop neuroprotective drugs, all of them failed at the clinical stage. It is well admitted that experimental models of stroke are either too severe, not enough reproducible, or do not sufficiently mimic pathophysiology of the Human disease for a correct evaluation of drugs efficacy including neuroprotectants, thrombolytics alone or in combination.

In order to solve this problem, ESRP scientists developed a new translational model of thromboembolic stroke in mice, which overcomes several of these pitfalls. This model is now available for pharmacological studies with Strok@lliance.

In situ thromboembolic  stroke is induced by the injection of purified thrombin in the Middle Cerebral Artery (MCA) at M1/M2 bifurcation, modelling a distal thrombosis eligible for thrombolytic treatments in humans. It results in reproducible ischemic lesions in the somatosensory cortex (≈20 mm3 ; Fig. 1). Moreover, it produces a significant strength deficit of the contralateral paws, lasting up to 14 days after stroke onset thus allowing functional recovery studies.


Figure 1. A. Thrombin injection in the MCA at M1/M2 bifurcation; B. Cerebral blood flow reduction in the ischemic hemisphere at stroke onset (laser speckle imaging); C. Representative lesion at 24h after stroke onset in saline-treated mice (T2* MRI).


Due to its fibrin-rich content, the produced clot is sensitive to rt-PA induced thrombolysis. A retrospective data analysis from 26 preclinical studies performed with this model in 9 independent academic laboratories allowed to estimate the therapeutic windows of rt-PA on cerebral lesion volume. When started early after stroke onset, i.e. less than 40 min post-stroke, rt-PA treatment induces a reproducible reduction of the cerebral injury; treatment starting later than 90 min had no or deleterious effects. This study also confirmed the intra- and inter-laboratory reproducibility of this model (Fig. 2).

Thus, this model reproduces key features of human pathophysiology and pharmacology, while overcoming several pitfalls of classical models.


Figure 2. Effects of rt-PA i.v. perfused at 10 mg/kg when administered 30 min or 4 hours after stroke onset on: A. infarct volume and B. Brain oedema. Data are expressed as mean ± SEM. *** P < 0.001 versus saline.


Orset C. et al. (2007) Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 38:2771-8.

Macrez R. et al. (2011) Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke 42:2315-22.

El Amki M. et al. (2012) Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke. Experimental neurology 238:138-44.



“Composed of highly skilled specialists, Strok@lliance is now able to manage projects for the pharmaceutical industry, ensuring that both expertise and creativity are brought into play in providing high-level animal studies in a quality-controlled environment. By taking full advantage of the CYCERON facilities, Strok@lliance accesses state-of-the-art technology and offers fine-tuned behavioral studies.”


N. Violle, Etap-Lab CEO, Strok@lliance Executive Partner


 Meet us at ESOC 2017

Dr. Nicolas VIOLLE will attend to the 3rd European Stroke Organization Conference ​ (ESOC) from 16-18 May, 2017 (Prague).

ESOC is one of the most exiting conference this year about clinical trials and developments in stroke management, treatment and prevention.
It will be the occasion for us to meet leaders from pharmaceutical industry to present STROM@LLIANCE, the new service 100% dedicated to preclinical stroke research.

Contact us from now to schedule a meeting.

May 10th, 2017 – 11:00 AM – 4:30 PM

28 Rue Saint-Dominique, 75007 Paris


Launch of STROK@LLIANCE, the new preclinical platform resulting from the alliance of the public Experimental Stroke Research Platform (ESRP) and the well-established CRO ETAP-Lab.

For half a day, neurologists, neuroradiologists, neurosurgeons, researchers, specialists in preclinical and clinical trials, will give you an overview of stroke etiology, current acute management practices and animal modeling. Next, they will discuss with you during a debate: “The transition from preclinical drug to clinical drug for stroke: What are the essential information for clinicians about pharmacology issues?”

Final Program May 10th